2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to Do
Authors: Milda Saunders, Neda Laiteerapong
Journal: Annals of Internal Medicine (2023)

EditorialsMarch 20232022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease: An Important First Step, More Work to DoCorrection(s) for this article:CorrectionsMar 2023Correction: 2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney DiseaseFREEMilda Saunders, MD, MPH and Neda Laiteerapong, MD, MSMilda Saunders, MD, MPHSection of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, Illinois and Neda Laiteerapong, MD, MSSection of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, IllinoisAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-3635 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In their article, Navaneethan and colleagues (1) present a synopsis of a 2022 clinical practice guideline update for diabetes management in chronic kidney disease (CKD) (1). They report changes to the Kidney Disease: Improving Global Outcomes (KDIGO) 2020 guidelines in 2 areas, comprehensive care and glucose-lowering therapies in patients with type 2 diabetes and CKD. The KDIGO 2022 guidelines build on high-quality evidence that supports newer medications to prevent CKD progression and CKD-associated complications (2). These updated recommendations are exciting for their potential to change the natural history of CKD and diabetes, but their effect could be highly limited by ...References1. Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the 2022 KDIGO clinical practice guideline update. Ann Intern Med. 2022;176:381-7. doi:10.7326/M22-2904 LinkGoogle Scholar2. Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline. Ann Intern Med. 2021;174:385-394. [PMID: 33166222] doi:10.7326/M20-5938 LinkGoogle Scholar3. Baumann AA, Cabassa LJ. Reframing implementation science to address inequities in healthcare delivery. BMC Health Serv Res. 2020;20:190. [PMID: 32164706] doi:10.1186/s12913-020-4975-3 CrossrefMedlineGoogle Scholar4. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2022. Google Scholar5. McCoy RG, Dykhoff HJ, Sangaralingham L, et al. Adoption of new glucose-lowering medications in the U.S.—the case of SGLT2 inhibitors: nationwide cohort study. Diabetes Technol Ther. 2019;21:702-712. [PMID: 31418588] doi:10.1089/dia.2019.0213 CrossrefMedlineGoogle Scholar6. McCoy RG, Van Houten HK, Karaca-Mandic P, et al. Second-line therapy for type 2 diabetes management: the treatment/benefit paradox of cardiovascular and kidney comorbidities. Diabetes Care. 2021;44:2302-11. [PMID: 34348996] doi:10.2337/dc20-2977 CrossrefMedlineGoogle Scholar7. Aghajani Nargesi A, Clark C, Liu M, et al. Access to specialty cardiovascular care and uptake of cardioprotective anti-hyperglycemic agents among adults with type 2 diabetes: a cohort study [Abstract]. Circulation. 2022;146(suppl 1):A10019. AHA Scientific Sessions abstract 10019. doi:10.1161/circ.146.suppl_1.10019 CrossrefGoogle Scholar8. Chiu N, Aggarwal R, Bakris GL, et al. Generalizability of FIGARO-DKD and FIDELIO-DKD trial criteria to the US population eligible for finerenone [Letter]. J Am Heart Assoc. 2022;11:e025079. [PMID: 35311349] doi:10.1161/JAHA.121.025079 CrossrefMedlineGoogle Scholar9. Porter J, Boyd C, Skandari MR, et al. Revisiting the time needed to provide adult primary care. J Gen Intern Med. 2022. [PMID: 35776372] doi:10.1007/s11606-022-07707-x CrossrefMedlineGoogle Scholar10. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2022;102:974-989. [PMID: 36202661] doi:10.1016/j.kint.2022.08.012 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Section of General Internal Medicine and Center for Chronic Disease Research and Policy, Department of Medicine, University of Chicago, Chicago, IllinoisDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M22-3635.Corresponding Author: Neda Laiteerapong, MD, MS, University of Chicago, 5841 South Maryland Avenue, MC 2007B, Chicago, IL 60637; e-mail, [email protected]uchicago.edu.Correction: This article was corrected on 17 January 2023 to clarify the collaboration between KDIGO and ADA, and to add a reference. A correction has been published (doi:10.7326/L23-0010).This article was published at Annals.org on 10 January 2023. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDiabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update Sankar D. Navaneethan , Sophia Zoungas , M. Luiza Caramori , Juliana C.N. Chan , Hiddo J.L. Heerspink , Clint Hurst , Adrian Liew , Erin D. Michos , Wasiu A. Olowu , Tami Sadusky , Nikhil Tandon , Katherine R. Tuttle , Christoph Wanner , Katy G. Wilkens , Jonathan C. Craig , David J. Tunnicliffe , Marcello Tonelli , Michael Cheung , Amy Earley , Peter Rossing , Ian H. de Boer , and Kamlesh Khunti Correction: 2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease Metrics Cited byCorrection: 2022 Clinical Practice Guideline Update for Diabetes Management of Chronic Kidney Disease Current IssueMarch 2023Volume 176, Issue 3Page: 417-418KeywordsCardiovascular diseasesChronic kidney diseaseEstimated glomerular filtration rateRenal diseasesResearch designSodium-glucose cotransporter-2 inhibitorsTreatment guidelinesType 2 diabetes ePublished: 10 January 2023 Issue Published: March 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...